Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some adverse-effect claims (GI symptoms, depression, weight loss) are supported by the provided label text, but several safety-related claims regarding infections, infection monitoring/red flags, dehydration, and headache are not supported by the supplied label sections. Several “red-flag” and monitoring statements extend beyond what is shown in the available prescribing information.
Category Scores
Accurate Statements
Apremilast (Otezla) can cause gastrointestinal symptoms, including diarrhea, nausea, and vomiting.
Supported by 5.2 and 6 (Diarrhea, Nausea, and Vomiting).
Apremilast can cause weight loss.
Supported by 5.4 and 6 (Weight Decrease).
Mood changes, including depression, have been reported with apremilast.
Supported by 5.3 and 6 (Depression).
Red-flag side effects of apremilast include worsening mood or suicidal thoughts.
Supported by 5.3 and 17 (Depression).
Clinicians may track body weight over time during apremilast treatment and evaluate whether ongoing treatment is appropriate if weight drops significantly.
Supported by 5.4 (regularly monitor weight; evaluate and consider discontinuation if unexplained or clinically significant weight loss occurs).
Unsupported Statements
Apremilast can cause headache.
Not supported by the provided label sections (no headache adverse reaction or warning text in 5 and 6 excerpts).
Serious infections are a concern with apremilast.
No serious infections warning/precaution or adverse reaction text provided in the supplied label sections (5 and 6 excerpts).
Patients should watch for signs of infection with apremilast (e.g., fever, persistent cough, or unusual tiredness).
No infection monitoring/red-flag guidance provided in the supplied label sections (5 and 17 excerpts).
Severe gastrointestinal side effects from apremilast may lead to dehydration.
5.2 discusses complications from severe diarrhea/nausea/vomiting and higher risk patients, but the supplied text does not state dehydration may occur.
Red-flag side effects of apremilast include signs of a serious infection.
No serious infection safety information or patient monitoring/red-flag guidance provided in the supplied label sections (5 and 17 excerpts).
Contradictions
Important Omissions
For severe diarrhea, nausea, or vomiting, the label specifically says to consider OTEZLA/OTEZLA XR dosage reduction or suspension (not merely supportive care and/or changing dosing plan generally).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response correctly identifies some label-supported risks (severe GI symptoms, depression, weight loss monitoring). However, it adds infection-related concerns and specific infection monitoring/red-flag examples without support in the provided label sections, and it states dehydration may occur, which is not supported by the supplied text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Several safety claims (headache; serious infection concern and infection red-flag monitoring; dehydration from GI side effects; infection red flags) are not supported by the provided label excerpts.
Suggested Improvement
Remove or rephrase infection-related and dehydration statements unless supported by additional label sections. Align GI management phrasing with the label wording (consider dosage reduction or suspension for severe diarrhea/nausea/vomiting) and restrict “red-flag” examples to those explicitly described in the supplied labeling (e.g., depression/suicidal thoughts; clinically significant/unexplained weight loss; contact provider for severe GI reactions).